The epidemiology of Atopobium vaginae is the study of the distribution and determinants of this bacterium in human populations. A. vaginae is one of the most common microorganisms associated with bacterial vaginosis (BV); 30% of women of reproductive age globally may be affected. A disturbance of the normal vaginal microbiome is a feature of BV, which is usually dominated by lactobacilli, and a replacement by anaerobic and facultative anaerobic bacteria, such as Gardnerella vaginalis, Mycoplasma hominis, Prevotella spp., and A. vaginae.
It was first isolated from the human vagina in 1984 by Collins et al., who named it Peptostreptococcus parvulus. Later, it was reclassified as Atopobium parvulum by Ezaki et al., and finally as A. vaginae by Falsen et al.… A. vaginae has a high 16S rRNA gene similarity (>99%) with other Atopobium species, such as A. minutum and A. rimae. Still, it can be distinguished by its biochemical characteristics, such as its ability to produce acid from glucose and maltose.
A. vaginae is not always detected in healthy women but is frequently found in women with BV. The prevalence of A. vaginae in virginal women is low (7%), but it increases significantly in women with nonpenetrative sexual contact, such as oral sex or hand-genital contact. It suggests that A. vaginae can be transmitted through sexual activity, even without vaginal penetration. A. vaginae is also more prevalent in women with multiple sexual partners, use intrauterine devices, or have a history of sexually transmitted infections.
A. vaginae plays an essential role in the pathogenesis and persistence of BV. It has been shown to form biofilms with G. vaginalis on the vaginal epithelium; This could defend the bacteria against the host’s immune system and antimicrobial agents. A. vaginae also produces lactic acid and acetic acid, which lower the vaginal pH and create a favorable environment for the growth of other anaerobes. Moreover, A. vaginae is resistant to antibiotics commonly used to treat BV, such as metronidazole and clindamycin. Therefore, it is essential to consider the presence of A. vaginae when choosing a treatment for BV.
Kingdom: Bacteria
Phylum: Actinomycetota
Class: Coriobacteriia
Order: Coriobacteriales
Family: Atopobiaceae
Genus: Atopobium
Species: A. vaginae
The structure of Atopobium vaginae is the shape and arrangement of this bacterium, which is associated with bacterial vaginosis (BV), a condition that affects the vaginal microbiota. Some of the main features of the structure of A. vaginae are:
A. vaginae is an anaerobic Gram-positive bacterium, which means that it does not require oxygen to grow and has a thick cell wall that retains a purple stain when exposed to a special dye.
A. vaginae is elliptical or rod-shaped, meaning it has an oval or cylindrical form.
A. vaginae is nonmotile and non-spore-forming, which means it does not have structures that allow it to move or survive in harsh conditions.
A. vaginae occurs alone, in pairs, in clumps, or in short chains, meaning it can be found as single cells or as groups of cells attached.
The antigenic types of Atopobium vaginae are the different forms of this bacterium that can elicit an immune response from the host. According to the web search results, not much information is available on the antigenic types of A. vaginae. Still, some studies have suggested that this bacterium may have different strains or species that vary in their genetic and phenotypic characteristics.
A. vaginae may have different antigenic types that could affect its role in the pathogenesis and treatment of bacterial vaginosis (BV), a condition characterized by disrupting the normal lactobacilli-dominated vaginal microbiota. However, more research is needed to confirm the antigenic diversity and variability of A. vaginae and its clinical implications.
The pathogenesis of Atopobium vaginae is the process by which this bacterium causes or contributes to bacterial vaginosis (BV), a circumstance identified by the disruption of the normal vaginal microbiota. Here are five points to summarize the pathogenesis of A. vaginae:
A. vaginae is a gram-positive, anaerobic coccobacillus that belongs to the Actinobacteria phylum and the Coriobacteriaceae family. It is one of the most common microorganisms associated with BV, Gardnerella vaginalis, Mycoplasma hominis, Prevotella spp., and others.
A. vaginae is not always detected in healthy women but is frequently found in women with BV. The prevalence of A. vaginae increases significantly in women with sexual contact, multiple sexual partners, intrauterine devices, or a history of sexually transmitted infections. It suggests that A. vaginae can be transmitted through sexual activity, hurting women’s reproductive health.
A. vaginae plays an essential role in the pathophysiology of BV by forming biofilms with G. vaginalis on the vaginal epithelium. Complex bacterial colonies that attach to a surface form biofilms protected by a matrix of extracellular polymeric substances. Biofilms may protect A. vaginae and other BV-associated Antimicrobials and microorganisms from the host immune system.
A. vaginae also produces lactic acid and acetic acid, which lower the vaginal pH and create a favorable environment for the growth of other anaerobes. Moreover, A. vaginae is resistant to antibiotics commonly used to treat BV, such as metronidazole and clindamycin. Therefore, it is essential to consider the presence of A. vaginae when choosing a treatment for BV.
A. vaginae induces the synthesis of localized IL-6 and IL-8 as well as the antimicrobial peptide -defensin after activating the toll-like receptor 2 in epithelial cells. It may contribute to the inflammation and tissue damage associated with BV. A. vaginae is also linked to several adverse health outcomes in women, especially during pregnancy, such as preterm delivery, low birth weight, chorioamnionitis, endometritis, and pelvic inflammatory disease. A. vaginae may also facilitate the transmission of other pathogens, such as HIV, herpes simplex virus type 2, human papillomavirus, and Neisseria gonorrhoeae.
The host defenses of Atopobium vaginae are the mechanisms by which this bacterium evades or resists the immune system and antibiotics of the human host. Some of the primary host defenses of A. vaginae are:
A. vaginae is involved in forming biofilms, complex communities of bacteria that adhere to the vaginal epithelium and are resistant to antibiotics and host defenses. A. vaginae can form biofilms with other BV-associated bacteria, such as Gardnerella vaginalis, and produce extracellular matrix components, such as exopolysaccharides and proteins.
A. vaginae can stimulate epithelial cells to produce localized IL-6 and IL-8 and the antimicrobial peptide -defensin after activating the toll-like receptor 2. It may contribute to the inflammation and tissue damage associated with BV.
A. vaginae may resist some common antibiotics used to treat BV, including clindamycin and metronidazole. It may contribute to the high recurrence rate of BV.
A. vaginae can be transmitted by nonpenetrative sexual contact, such as oral sex and hand-genital contact, as well as by genital-genital contact. It is more prevalent in women who have participated in oral sex or hand-genital contact without penetration than in those who have not.
Bacterial vaginosis (BV) and Atopobium vaginae are related, which disrupts the normal lactobacilli-dominated vaginal microbiota. BV can cause various clinical manifestations, such as:
Increased vaginal discharge of grayish or whitish color, milky consistency, and fishy smell, especially after sexual intercourse.
Vaginal burning, dysuria (painful urination), and dyspareunia (painful intercourse).
Itching sensation, burning, and pain in the vulva (external genitalia)
risk of contracting STIs (sexually transmitted illnesses) rising, pelvic inflammatory disease (PID), endometritis (inflammation of the uterine lining), tubo-ovarian abscesses (infection of the ovaries and fallopian tubes), and preterm delivery with neonatal consequences.
Not all women with BV have symptoms; some may have only mild or moderate signs of infection. However, it is essential to seek medical attention if you suspect you have BV, as untreated BV can lead to severe complications.
The diagnosis of Atopobium vaginae identifies and confirms the presence of this bacterium in the vaginal microbiota, especially in bacterial vaginosis (BV).
Some of the primary methods for the diagnosis of A. vaginae are:
Clinical criteria: The diagnosis of BV is usually based on the clinical criteria of Amsel or Nugent, which involve the examination of vaginal discharge, pH, odor, and microscopic appearance of the vaginal flora. However, these methods are not very sensitive or specific for detecting A. vaginae, as this bacterium is not always present in BV and can also be found in some women with normal flora.
Molecular methods: These methods are more sensitive and specific than conventional methods for identifying BV-related microorganisms, such as A. vaginae. They include polymerase chain reaction (PCR) and fluorescence in situ hybridization (FISH), which use DNA probes to target and amplify specific bacterial genes or sequences. These methods can also provide information about the bacterial load, diversity, and biofilm formation of A. vaginae and other BV-related bacteria.
Atopobium vaginae prevention is linked to bacterial vaginosis prevention since both conditions involve alteration of the typical lactobacilli-dominated vaginal flora. Some of the possible ways to prevent BV and A. vaginae are:
Avoid douching, which can disturb the risk of BV is increased by the average balance of microorganisms in the vagina.
Using unscented products for genital hygiene, such as soaps, tampons, or pads, which can irritate the vaginal tissues and alter the pH.
Washing the genitals with warm water only, as the vagina does not require cleansing other than regular bathing.
Practicing safe sex, such as condoms or dental dams, can reduce the transmission of A. vaginae and other BV-associated bacteria.
Quitting smoking can impair the immune system and increase susceptibility to BV.
Using hormonal contraception, such as oral pills or intrauterine devices, can help maintain a stable vaginal environment and prevent BV recurrence.
Taking probiotics can restore the beneficial lactobacilli in the vagina and inhibit the growth of A. vaginae and other BV-related bacteria.
An update on the role of Atopobium vaginae in bacterial vaginosis: what to consider when choosing a treatment? A mini review | Archives of Gynecology and Obstetrics (springer.com)
The epidemiology of Atopobium vaginae is the study of the distribution and determinants of this bacterium in human populations. A. vaginae is one of the most common microorganisms associated with bacterial vaginosis (BV); 30% of women of reproductive age globally may be affected. A disturbance of the normal vaginal microbiome is a feature of BV, which is usually dominated by lactobacilli, and a replacement by anaerobic and facultative anaerobic bacteria, such as Gardnerella vaginalis, Mycoplasma hominis, Prevotella spp., and A. vaginae.
It was first isolated from the human vagina in 1984 by Collins et al., who named it Peptostreptococcus parvulus. Later, it was reclassified as Atopobium parvulum by Ezaki et al., and finally as A. vaginae by Falsen et al.… A. vaginae has a high 16S rRNA gene similarity (>99%) with other Atopobium species, such as A. minutum and A. rimae. Still, it can be distinguished by its biochemical characteristics, such as its ability to produce acid from glucose and maltose.
A. vaginae is not always detected in healthy women but is frequently found in women with BV. The prevalence of A. vaginae in virginal women is low (7%), but it increases significantly in women with nonpenetrative sexual contact, such as oral sex or hand-genital contact. It suggests that A. vaginae can be transmitted through sexual activity, even without vaginal penetration. A. vaginae is also more prevalent in women with multiple sexual partners, use intrauterine devices, or have a history of sexually transmitted infections.
A. vaginae plays an essential role in the pathogenesis and persistence of BV. It has been shown to form biofilms with G. vaginalis on the vaginal epithelium; This could defend the bacteria against the host’s immune system and antimicrobial agents. A. vaginae also produces lactic acid and acetic acid, which lower the vaginal pH and create a favorable environment for the growth of other anaerobes. Moreover, A. vaginae is resistant to antibiotics commonly used to treat BV, such as metronidazole and clindamycin. Therefore, it is essential to consider the presence of A. vaginae when choosing a treatment for BV.
Kingdom: Bacteria
Phylum: Actinomycetota
Class: Coriobacteriia
Order: Coriobacteriales
Family: Atopobiaceae
Genus: Atopobium
Species: A. vaginae
The structure of Atopobium vaginae is the shape and arrangement of this bacterium, which is associated with bacterial vaginosis (BV), a condition that affects the vaginal microbiota. Some of the main features of the structure of A. vaginae are:
A. vaginae is an anaerobic Gram-positive bacterium, which means that it does not require oxygen to grow and has a thick cell wall that retains a purple stain when exposed to a special dye.
A. vaginae is elliptical or rod-shaped, meaning it has an oval or cylindrical form.
A. vaginae is nonmotile and non-spore-forming, which means it does not have structures that allow it to move or survive in harsh conditions.
A. vaginae occurs alone, in pairs, in clumps, or in short chains, meaning it can be found as single cells or as groups of cells attached.
The antigenic types of Atopobium vaginae are the different forms of this bacterium that can elicit an immune response from the host. According to the web search results, not much information is available on the antigenic types of A. vaginae. Still, some studies have suggested that this bacterium may have different strains or species that vary in their genetic and phenotypic characteristics.
A. vaginae may have different antigenic types that could affect its role in the pathogenesis and treatment of bacterial vaginosis (BV), a condition characterized by disrupting the normal lactobacilli-dominated vaginal microbiota. However, more research is needed to confirm the antigenic diversity and variability of A. vaginae and its clinical implications.
The pathogenesis of Atopobium vaginae is the process by which this bacterium causes or contributes to bacterial vaginosis (BV), a circumstance identified by the disruption of the normal vaginal microbiota. Here are five points to summarize the pathogenesis of A. vaginae:
A. vaginae is a gram-positive, anaerobic coccobacillus that belongs to the Actinobacteria phylum and the Coriobacteriaceae family. It is one of the most common microorganisms associated with BV, Gardnerella vaginalis, Mycoplasma hominis, Prevotella spp., and others.
A. vaginae is not always detected in healthy women but is frequently found in women with BV. The prevalence of A. vaginae increases significantly in women with sexual contact, multiple sexual partners, intrauterine devices, or a history of sexually transmitted infections. It suggests that A. vaginae can be transmitted through sexual activity, hurting women’s reproductive health.
A. vaginae plays an essential role in the pathophysiology of BV by forming biofilms with G. vaginalis on the vaginal epithelium. Complex bacterial colonies that attach to a surface form biofilms protected by a matrix of extracellular polymeric substances. Biofilms may protect A. vaginae and other BV-associated Antimicrobials and microorganisms from the host immune system.
A. vaginae also produces lactic acid and acetic acid, which lower the vaginal pH and create a favorable environment for the growth of other anaerobes. Moreover, A. vaginae is resistant to antibiotics commonly used to treat BV, such as metronidazole and clindamycin. Therefore, it is essential to consider the presence of A. vaginae when choosing a treatment for BV.
A. vaginae induces the synthesis of localized IL-6 and IL-8 as well as the antimicrobial peptide -defensin after activating the toll-like receptor 2 in epithelial cells. It may contribute to the inflammation and tissue damage associated with BV. A. vaginae is also linked to several adverse health outcomes in women, especially during pregnancy, such as preterm delivery, low birth weight, chorioamnionitis, endometritis, and pelvic inflammatory disease. A. vaginae may also facilitate the transmission of other pathogens, such as HIV, herpes simplex virus type 2, human papillomavirus, and Neisseria gonorrhoeae.
The host defenses of Atopobium vaginae are the mechanisms by which this bacterium evades or resists the immune system and antibiotics of the human host. Some of the primary host defenses of A. vaginae are:
A. vaginae is involved in forming biofilms, complex communities of bacteria that adhere to the vaginal epithelium and are resistant to antibiotics and host defenses. A. vaginae can form biofilms with other BV-associated bacteria, such as Gardnerella vaginalis, and produce extracellular matrix components, such as exopolysaccharides and proteins.
A. vaginae can stimulate epithelial cells to produce localized IL-6 and IL-8 and the antimicrobial peptide -defensin after activating the toll-like receptor 2. It may contribute to the inflammation and tissue damage associated with BV.
A. vaginae may resist some common antibiotics used to treat BV, including clindamycin and metronidazole. It may contribute to the high recurrence rate of BV.
A. vaginae can be transmitted by nonpenetrative sexual contact, such as oral sex and hand-genital contact, as well as by genital-genital contact. It is more prevalent in women who have participated in oral sex or hand-genital contact without penetration than in those who have not.
Bacterial vaginosis (BV) and Atopobium vaginae are related, which disrupts the normal lactobacilli-dominated vaginal microbiota. BV can cause various clinical manifestations, such as:
Increased vaginal discharge of grayish or whitish color, milky consistency, and fishy smell, especially after sexual intercourse.
Vaginal burning, dysuria (painful urination), and dyspareunia (painful intercourse).
Itching sensation, burning, and pain in the vulva (external genitalia)
risk of contracting STIs (sexually transmitted illnesses) rising, pelvic inflammatory disease (PID), endometritis (inflammation of the uterine lining), tubo-ovarian abscesses (infection of the ovaries and fallopian tubes), and preterm delivery with neonatal consequences.
Not all women with BV have symptoms; some may have only mild or moderate signs of infection. However, it is essential to seek medical attention if you suspect you have BV, as untreated BV can lead to severe complications.
The diagnosis of Atopobium vaginae identifies and confirms the presence of this bacterium in the vaginal microbiota, especially in bacterial vaginosis (BV).
Some of the primary methods for the diagnosis of A. vaginae are:
Clinical criteria: The diagnosis of BV is usually based on the clinical criteria of Amsel or Nugent, which involve the examination of vaginal discharge, pH, odor, and microscopic appearance of the vaginal flora. However, these methods are not very sensitive or specific for detecting A. vaginae, as this bacterium is not always present in BV and can also be found in some women with normal flora.
Molecular methods: These methods are more sensitive and specific than conventional methods for identifying BV-related microorganisms, such as A. vaginae. They include polymerase chain reaction (PCR) and fluorescence in situ hybridization (FISH), which use DNA probes to target and amplify specific bacterial genes or sequences. These methods can also provide information about the bacterial load, diversity, and biofilm formation of A. vaginae and other BV-related bacteria.
Atopobium vaginae prevention is linked to bacterial vaginosis prevention since both conditions involve alteration of the typical lactobacilli-dominated vaginal flora. Some of the possible ways to prevent BV and A. vaginae are:
Avoid douching, which can disturb the risk of BV is increased by the average balance of microorganisms in the vagina.
Using unscented products for genital hygiene, such as soaps, tampons, or pads, which can irritate the vaginal tissues and alter the pH.
Washing the genitals with warm water only, as the vagina does not require cleansing other than regular bathing.
Practicing safe sex, such as condoms or dental dams, can reduce the transmission of A. vaginae and other BV-associated bacteria.
Quitting smoking can impair the immune system and increase susceptibility to BV.
Using hormonal contraception, such as oral pills or intrauterine devices, can help maintain a stable vaginal environment and prevent BV recurrence.
Taking probiotics can restore the beneficial lactobacilli in the vagina and inhibit the growth of A. vaginae and other BV-related bacteria.
An update on the role of Atopobium vaginae in bacterial vaginosis: what to consider when choosing a treatment? A mini review | Archives of Gynecology and Obstetrics (springer.com)
The epidemiology of Atopobium vaginae is the study of the distribution and determinants of this bacterium in human populations. A. vaginae is one of the most common microorganisms associated with bacterial vaginosis (BV); 30% of women of reproductive age globally may be affected. A disturbance of the normal vaginal microbiome is a feature of BV, which is usually dominated by lactobacilli, and a replacement by anaerobic and facultative anaerobic bacteria, such as Gardnerella vaginalis, Mycoplasma hominis, Prevotella spp., and A. vaginae.
It was first isolated from the human vagina in 1984 by Collins et al., who named it Peptostreptococcus parvulus. Later, it was reclassified as Atopobium parvulum by Ezaki et al., and finally as A. vaginae by Falsen et al.… A. vaginae has a high 16S rRNA gene similarity (>99%) with other Atopobium species, such as A. minutum and A. rimae. Still, it can be distinguished by its biochemical characteristics, such as its ability to produce acid from glucose and maltose.
A. vaginae is not always detected in healthy women but is frequently found in women with BV. The prevalence of A. vaginae in virginal women is low (7%), but it increases significantly in women with nonpenetrative sexual contact, such as oral sex or hand-genital contact. It suggests that A. vaginae can be transmitted through sexual activity, even without vaginal penetration. A. vaginae is also more prevalent in women with multiple sexual partners, use intrauterine devices, or have a history of sexually transmitted infections.
A. vaginae plays an essential role in the pathogenesis and persistence of BV. It has been shown to form biofilms with G. vaginalis on the vaginal epithelium; This could defend the bacteria against the host’s immune system and antimicrobial agents. A. vaginae also produces lactic acid and acetic acid, which lower the vaginal pH and create a favorable environment for the growth of other anaerobes. Moreover, A. vaginae is resistant to antibiotics commonly used to treat BV, such as metronidazole and clindamycin. Therefore, it is essential to consider the presence of A. vaginae when choosing a treatment for BV.
Kingdom: Bacteria
Phylum: Actinomycetota
Class: Coriobacteriia
Order: Coriobacteriales
Family: Atopobiaceae
Genus: Atopobium
Species: A. vaginae
The structure of Atopobium vaginae is the shape and arrangement of this bacterium, which is associated with bacterial vaginosis (BV), a condition that affects the vaginal microbiota. Some of the main features of the structure of A. vaginae are:
A. vaginae is an anaerobic Gram-positive bacterium, which means that it does not require oxygen to grow and has a thick cell wall that retains a purple stain when exposed to a special dye.
A. vaginae is elliptical or rod-shaped, meaning it has an oval or cylindrical form.
A. vaginae is nonmotile and non-spore-forming, which means it does not have structures that allow it to move or survive in harsh conditions.
A. vaginae occurs alone, in pairs, in clumps, or in short chains, meaning it can be found as single cells or as groups of cells attached.
The antigenic types of Atopobium vaginae are the different forms of this bacterium that can elicit an immune response from the host. According to the web search results, not much information is available on the antigenic types of A. vaginae. Still, some studies have suggested that this bacterium may have different strains or species that vary in their genetic and phenotypic characteristics.
A. vaginae may have different antigenic types that could affect its role in the pathogenesis and treatment of bacterial vaginosis (BV), a condition characterized by disrupting the normal lactobacilli-dominated vaginal microbiota. However, more research is needed to confirm the antigenic diversity and variability of A. vaginae and its clinical implications.
The pathogenesis of Atopobium vaginae is the process by which this bacterium causes or contributes to bacterial vaginosis (BV), a circumstance identified by the disruption of the normal vaginal microbiota. Here are five points to summarize the pathogenesis of A. vaginae:
A. vaginae is a gram-positive, anaerobic coccobacillus that belongs to the Actinobacteria phylum and the Coriobacteriaceae family. It is one of the most common microorganisms associated with BV, Gardnerella vaginalis, Mycoplasma hominis, Prevotella spp., and others.
A. vaginae is not always detected in healthy women but is frequently found in women with BV. The prevalence of A. vaginae increases significantly in women with sexual contact, multiple sexual partners, intrauterine devices, or a history of sexually transmitted infections. It suggests that A. vaginae can be transmitted through sexual activity, hurting women’s reproductive health.
A. vaginae plays an essential role in the pathophysiology of BV by forming biofilms with G. vaginalis on the vaginal epithelium. Complex bacterial colonies that attach to a surface form biofilms protected by a matrix of extracellular polymeric substances. Biofilms may protect A. vaginae and other BV-associated Antimicrobials and microorganisms from the host immune system.
A. vaginae also produces lactic acid and acetic acid, which lower the vaginal pH and create a favorable environment for the growth of other anaerobes. Moreover, A. vaginae is resistant to antibiotics commonly used to treat BV, such as metronidazole and clindamycin. Therefore, it is essential to consider the presence of A. vaginae when choosing a treatment for BV.
A. vaginae induces the synthesis of localized IL-6 and IL-8 as well as the antimicrobial peptide -defensin after activating the toll-like receptor 2 in epithelial cells. It may contribute to the inflammation and tissue damage associated with BV. A. vaginae is also linked to several adverse health outcomes in women, especially during pregnancy, such as preterm delivery, low birth weight, chorioamnionitis, endometritis, and pelvic inflammatory disease. A. vaginae may also facilitate the transmission of other pathogens, such as HIV, herpes simplex virus type 2, human papillomavirus, and Neisseria gonorrhoeae.
The host defenses of Atopobium vaginae are the mechanisms by which this bacterium evades or resists the immune system and antibiotics of the human host. Some of the primary host defenses of A. vaginae are:
A. vaginae is involved in forming biofilms, complex communities of bacteria that adhere to the vaginal epithelium and are resistant to antibiotics and host defenses. A. vaginae can form biofilms with other BV-associated bacteria, such as Gardnerella vaginalis, and produce extracellular matrix components, such as exopolysaccharides and proteins.
A. vaginae can stimulate epithelial cells to produce localized IL-6 and IL-8 and the antimicrobial peptide -defensin after activating the toll-like receptor 2. It may contribute to the inflammation and tissue damage associated with BV.
A. vaginae may resist some common antibiotics used to treat BV, including clindamycin and metronidazole. It may contribute to the high recurrence rate of BV.
A. vaginae can be transmitted by nonpenetrative sexual contact, such as oral sex and hand-genital contact, as well as by genital-genital contact. It is more prevalent in women who have participated in oral sex or hand-genital contact without penetration than in those who have not.
Bacterial vaginosis (BV) and Atopobium vaginae are related, which disrupts the normal lactobacilli-dominated vaginal microbiota. BV can cause various clinical manifestations, such as:
Increased vaginal discharge of grayish or whitish color, milky consistency, and fishy smell, especially after sexual intercourse.
Vaginal burning, dysuria (painful urination), and dyspareunia (painful intercourse).
Itching sensation, burning, and pain in the vulva (external genitalia)
risk of contracting STIs (sexually transmitted illnesses) rising, pelvic inflammatory disease (PID), endometritis (inflammation of the uterine lining), tubo-ovarian abscesses (infection of the ovaries and fallopian tubes), and preterm delivery with neonatal consequences.
Not all women with BV have symptoms; some may have only mild or moderate signs of infection. However, it is essential to seek medical attention if you suspect you have BV, as untreated BV can lead to severe complications.
The diagnosis of Atopobium vaginae identifies and confirms the presence of this bacterium in the vaginal microbiota, especially in bacterial vaginosis (BV).
Some of the primary methods for the diagnosis of A. vaginae are:
Clinical criteria: The diagnosis of BV is usually based on the clinical criteria of Amsel or Nugent, which involve the examination of vaginal discharge, pH, odor, and microscopic appearance of the vaginal flora. However, these methods are not very sensitive or specific for detecting A. vaginae, as this bacterium is not always present in BV and can also be found in some women with normal flora.
Molecular methods: These methods are more sensitive and specific than conventional methods for identifying BV-related microorganisms, such as A. vaginae. They include polymerase chain reaction (PCR) and fluorescence in situ hybridization (FISH), which use DNA probes to target and amplify specific bacterial genes or sequences. These methods can also provide information about the bacterial load, diversity, and biofilm formation of A. vaginae and other BV-related bacteria.
Atopobium vaginae prevention is linked to bacterial vaginosis prevention since both conditions involve alteration of the typical lactobacilli-dominated vaginal flora. Some of the possible ways to prevent BV and A. vaginae are:
Avoid douching, which can disturb the risk of BV is increased by the average balance of microorganisms in the vagina.
Using unscented products for genital hygiene, such as soaps, tampons, or pads, which can irritate the vaginal tissues and alter the pH.
Washing the genitals with warm water only, as the vagina does not require cleansing other than regular bathing.
Practicing safe sex, such as condoms or dental dams, can reduce the transmission of A. vaginae and other BV-associated bacteria.
Quitting smoking can impair the immune system and increase susceptibility to BV.
Using hormonal contraception, such as oral pills or intrauterine devices, can help maintain a stable vaginal environment and prevent BV recurrence.
Taking probiotics can restore the beneficial lactobacilli in the vagina and inhibit the growth of A. vaginae and other BV-related bacteria.
An update on the role of Atopobium vaginae in bacterial vaginosis: what to consider when choosing a treatment? A mini review | Archives of Gynecology and Obstetrics (springer.com)
jear2012 (semanticscholar.org)
Loading...
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
